Last updated: May 30, 2026
COPIKTRA (duvelisib) Suppliers: Who Manufactures Active Ingredient, Finished Dosage, and Key Packaging
COPIKTRA (duvelisib) supplier and manufacturing supply-chain visibility is limited in public sources without tying to a specific strength, dosage form, and NDC at shipment level. With the information available here, no complete, accurate supplier list can be produced end-to-end (API + finished drug product + primary/secondary packaging) for COPIKTRA.
Who are COPIKTRA (duvelisib) suppliers for the API and finished drug product?
No complete supplier roster can be stated from the available data. Publicly indexed sources typically identify the FDA drug applicant labeler and, in some cases, contract manufacturing site data only after matching to specific NDC presentations.
API supplier visibility for duvelisib
Public disclosures for duvelisib bulk API suppliers are not consistently published in a way that supports an accurate, comprehensive supplier list across all marketed presentations.
Finished dosage manufacturing
Finished product manufacturing sites can vary by strength and time period due to contract manufacturing and site transfers. A fully accurate mapping requires NDC-specific verification.
Packaging component suppliers
Primary packaging (bottles, blisters, closures) and secondary packaging suppliers are generally not listed in public drug label data in a way that supports reliable, complete identification.
What contract manufacturers make COPIKTRA (duvelisib) tablets/capsules?
No definitive contract manufacturer assignments can be confirmed for COPIKTRA presentations from the data available here.
How presentation-level variation changes “who supplies what”
COPIKTRA has multiple strengths. Suppliers of finished dosage forms and packaging can change with:
- contract manufacturing switches
- lot-to-lot site assignment
- packaging line qualification changes
Without NDC-level reconciliation, naming specific contract manufacturers risks inaccuracy.
Which companies supply COPIKTRA packaging and distribution through major wholesalers?
Public wholesale distributor information identifies channels (who distributes), not the specific packaging suppliers used for COPIKTRA. No complete packaging supplier list can be provided.
Wholesaler distribution is not the same as manufacturing
Wholesalers and distributors typically do not equal the manufacturing supply chain and do not disclose packaging vendor identity in standardized public databases.
What is COPIKTRA’s FDA labeler, and does that equal the manufacturer?
The FDA “labeler” field (often the company listed for distribution/marketing) does not necessarily equal:
- API manufacturer
- drug product contract manufacturer
- packaging vendor
A supplier list requires direct manufacturing-site identification, which is not available in complete form here.
What Orange Book or FDA data shows about COPIKTRA manufacturing sites?
Orange Book listings can include product and patent info but do not provide a reliable, complete supplier map for API, packaging, or contract manufacturing across all COPIKTRA presentations.
How does COPIKTRA’s supply chain compare with other PI3K inhibitors’ sourcing model?
General industry patterns include:
- API made by specialized chemical manufacturers
- finished dosage produced by contract manufacturing organizations
- packaging from tiered vendors
However, COPIKTRA-specific supplier identity cannot be mapped accurately from the available data set.
Key Takeaways
- A complete, accurate COPIKTRA supplier list (API + finished drug product + packaging) cannot be produced from the information available here.
- Public labeler/distributor data is not sufficient to name API and contract manufacturing suppliers reliably across all COPIKTRA NDC presentations.
- Supplier identification needs NDC-specific and site-specific manufacturing evidence, which is not present in the available materials.
FAQs
- Does the COPIKTRA labeler equal the API supplier?
- How can COPIKTRA’s supplier list change by strength or NDC?
- Are COPIKTRA packaging suppliers listed in FDA databases?
- Do contract manufacturing assignments remain constant for COPIKTRA over time?
- What data sources typically provide the most reliable COPIKTRA supplier identification?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drugs@FDA. U.S. Food and Drug Administration.
